Financials in USD. Standardized financial statements.
A compact view of how InMed Pharmaceuticals Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $4.94M | $4.60M | $4.14M | $1.09M | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | +7.5% | +11.2% | +279.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $3.24M | $3.50M | $2.73M | $545,889 | $0 | $183,090 | $123,227 | $122,880 | $96,117 | $85,059 |
| Gross Profit? | $1.71M | $1.10M | $1.40M | $543,546 | $0 | -$183,090 | -$123,227 | -$122,880 | -$96,117 | -$85,059 |
| Gross Margin? | +34.5% | +23.9% | +33.9% | +49.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $9.62M | $9.24M | $9.78M | $14.34M | $12.17M | $8.97M | $13.52M | $8.85M | $3.44M | $1.84M |
| Operating Income? | -$7.92M | -$8.13M | -$8.38M | -$13.79M | -$12.17M | -$9.15M | -$13.52M | -$8.98M | -$4.38M | -$2.32M |
| EBITDA? | -$7.26M | -$7.06M | -$7.78M | -$13.28M | -$12.17M | -$8.76M | -$10.26M | -$8.85M | -$3.36M | -$1.77M |
| Income Before Tax | -$8.16M | -$7.67M | -$7.93M | -$18.60M | -$12.65M | -$8.94M | -$13.26M | -$8.89M | -$4.47M | -$2.38M |
| Income Tax Expense | $0 | $7,100 | $13,100 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$8.16M | -$7.68M | -$7.95M | -$18.60M | -$12.65M | -$8.94M | -$10.01M | -$8.89M | -$3.44M | -$1.84M |
| EPS? | $-8.36 | $-20.14 | $-64.92 | $-16582.00 | $-938.91 | $-1161.21 | $-1264.97 | $-1032.12 | $-810.55 | $-643.57 |
| Diluted EPS? | $-8.36 | $-20.14 | $-64.92 | $-16582.00 | $-938.91 | $-1161.21 | $-1264.97 | $-1032.12 | $-810.55 | $-643.57 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality